Physician profile
David A Charles
NPI 1487835179
$5,756.24
in general payments reported to CMS, 2019-2025
36 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $799 · 2021: $1,894 · 2022: $640 · 2023: $910 · 2024: $428 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,239.11 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,075.98 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $483.96 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $415.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $405.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $394.38 | 2021-2025 | Ubrelvy, Qulipta |
| Allergan, INC. | $358.95 | 2019-2020 | |
| Pfizer INC. | $142.50 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.06 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $131.05 | 2019-2025 | Capvaxive, Gardasil 9 |
| Abbott Laboratories | $119.72 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $104.91 | 2019-2025 | Veozah |
| Gilead Sciences, INC. | $81.59 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $81.55 | 2022-2023 | Linzess |
| Amgen INC. | $58.36 | 2024-2025 | Otezla, Repatha, Repatha |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.